UK market entry
Bringing a pharmaceutical product to the UK.
Manufacturers entering the UK face two problems at once: finding a commercial route to buyers, and working through the regulatory steps that sit alongside it. Ambe, a UK pharmaceutical business established in 1999, works with manufacturers on both.
Information needed
What to include in a first enquiry.
The more of this you can share, the more useful the first conversation will be.
- Product name, active ingredient, strength, pack size and presentation
- Current regulatory position, including the markets where the product is already authorised
- Territories already supplied, and any existing UK or European distribution arrangement
- Expected volumes, pricing expectation and the commercial model being considered
- Timing, and whether the approach is exploratory or backed by a decision to enter the UK
How we assess it
Three things we look at first.
Product fit for the UK market
UK demand, existing competition, presentation, and whether a realistic commercial route exists.
Regulatory position
What is already in place shapes which steps are needed and how long entry is likely to take.
Commercial practicality
Volume, pricing, supply reliability and expectations, considered before either side commits time.
Sales and regulatory
Two routes, one problem.
A product can be commercially attractive and still be a long way from being sold in the UK; another can be straightforward on the regulatory side and still have no buyers. Manufacturers approaching the UK for the first time often underestimate one side or the other.
Ambe helps on both the sales route and the regulatory steps that go with it. The balance depends on the product and where you are starting from, which is why the first conversation is about your position rather than a proposal.
Important limits
What cannot be assumed.
- An enquiry does not confirm that a product is suitable for the UK market.
- Regulatory outcomes, timelines and authorisations cannot be guaranteed; they depend on the product and the responsible authority.
- Market entry discussions do not imply distribution terms, exclusivity, volume commitments or pricing.
- Company information and documents may be requested before a discussion can progress.
Tell us about the product and where it stands.
Include the product, its regulatory position, the markets it already supplies, expected volumes and your timing for the UK.